表紙
市場調査レポート

中度乾癬:世界の治験レビュー

Moderate Psoriasis Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 318803
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
中度乾癬:世界の治験レビュー Moderate Psoriasis Global Clinical Trials Review, H2, 2014
出版日: 2014年10月31日 ページ情報: 英文 115 Pages
概要

当レポートでは、中度乾癬の臨床試験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、臨床試験を実施している主な製薬企業および研究機関のプロファイルなどを提供しています。

イントロダクション

  • 中度乾癬
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:免疫疾患治療薬の治験における中度乾癬の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:免疫疾患治療薬の治験における中度乾癬の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

中度乾癬治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson & Johnson
    • Pfizer Inc.
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Innovaderm Research Inc.
    • E. Merck KG
    • Eli Lilly and Company
  • 代表的な研究機関・病院の治験の概要
    • Rutgers, The State University of New Jersey
    • Tufts Medical Center
    • Dresden University of Technology
    • University of California, San Francisco
    • Academic Medical Center
    • Wake Forest University
    • University of Zurich
    • University of California, Irvine
    • Northwestern University
    • Hospital Universitario Reina Sofia

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2400CTIDB

GlobalData's clinical trial report, "Moderate Psoriasis Global Clinical Trials Review, H2, 2014" provides data on the Moderate Psoriasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Moderate Psoriasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Moderate Psoriasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Moderate Psoriasis
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Moderate Psoriasis to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Moderate Psoriasis to Immunology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Moderate Psoriasis
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Moderate Psoriasis Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Innovaderm Research Inc.
      • Clinical Trial Overview of Innovaderm Research Inc.
      • E. Merck KG
      • Clinical Trial Overview of E. Merck KG
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
    • Clinical Trial Overview of Top Institutes / Government
      • Rutgers, The State University of New Jersey
      • Clinical Trial Overview of Rutgers, The State University of New Jersey
      • Tufts Medical Center
      • Clinical Trial Overview of Tufts Medical Center
      • Dresden University of Technology
      • Clinical Trial Overview of Dresden University of Technology
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
      • Academic Medical Center
      • Clinical Trial Overview of Academic Medical Center
      • Wake Forest University
      • Clinical Trial Overview of Wake Forest University
      • University of Zurich
      • Clinical Trial Overview of University of Zurich
      • University of California, Irvine
      • Clinical Trial Overview of University of California, Irvine
      • Northwestern University
      • Clinical Trial Overview of Northwestern University
      • Hospital Universitario Reina Sofia
      • Clinical Trial Overview of Hospital Universitario Reina Sofia
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Moderate Psoriasis Therapeutics, Global, Clinical Trials by Region, 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Moderate Psoriasis to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Moderate Psoriasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Moderate Psoriasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Moderate Psoriasis to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Moderate Psoriasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Moderate Psoriasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Moderate Psoriasis Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Moderate Psoriasis Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Moderate Psoriasis Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Moderate Psoriasis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Innovaderm Research Inc., 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rutgers, The State University of New Jersey, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tufts Medical Center, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dresden University of Technology, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Academic Medical Center, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Wake Forest University, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Zurich, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Northwestern University, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospital Universitario Reina Sofia, 2014*

List of Figures

  • Moderate Psoriasis Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Moderate Psoriasis to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Moderate Psoriasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Moderate Psoriasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Moderate Psoriasis to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Moderate Psoriasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Moderate Psoriasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Moderate Psoriasis Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Moderate Psoriasis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Moderate Psoriasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top